All News

A prospective study evaluating the efficacy of an artificial intelligence (AI)–based clinical support system further demonstrated the reliability of AI or machine learning as a diagnostic tool in skin cancer.

A recent report highlights gaps in mortality rates between rural and urban Americans; debt relief does not improve mental health or credit scores, researchers find; worries about sun gazing effects surge.

Overall survival and complete response rates were comparable across a younger and an older cohort of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.

In this investigation, investigators sought insights into the safety and efficacy of chimeric antigen receptor (CAR) T-cell therapy in acute myeloid leukemia (AML), with a particular focus on how various patient subgroups fared for complete remission (CR).

HIV testing, treatment, and intervention session delivery were among some areas that saw challenges in properly addressing youth experiencing homelessness during an HIV prevention trial.

The Center on Health Equity and Access covered the burden faced by caregivers, transgender health care, pre-exposure prophylaxis uptake, disparities in postpartum mental health care, and cost-related medication nonadherence among patients with chronic obstructive pulmonary disease.

Digital technology being less accessible to adult patients with vision impairment (VI) could be a detriment to telemedicine accessibility.

Accelerated biological aging may be behind why some types of cancer are on the rise in young adults, researchers find.

Antibodies targeting the CXCL12 protein show potential to promote hair growth in conditions like androgenic alopecia (AGA) and alopecia areata (AA), offering hope for new treatment options.

There is discrepancy between the FDA’s accelerated approval decisions and clinical benefits in cancer treatments; former President Donald Trump’s video statement avoids a clear stance on national abortion legislation; 40% of therapists say they will increase their fees this year.

Raajit Rampal, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses the potential of a disease-modifying therapy in polycythemia vera, treating high-risk vs low-risk patients, and emerging therapies in the pipeline.

Analyzing trends from online conversations among patients with myasthenia gravis (MG), researchers found that issues with current treatments were mentioned in nearly 24% of conversations.

Most recently, the FDA’s Oncologic Drugs Advisory Committee unanimously voted to recommend ciltacabtagene autoleucel (Carvykti; Johnson & Johnson) in patients who have received at least 1 line of treatment for relapsed/refractory multiple myeloma (RRMM).

Researchers found that in vitro clot formulation and fibrinolysis assays were able to determine the hemostatic effects of different replacement agents, as well as identify distinct pharmacodynamic responses across the different mechanisms of action.

A recent study found a minor link between prolactin levels and the risk of developing estrogen receptor (ER)-positive or ER-negative breast cancers. However, there was no association found between the use of selective serotonin reuptake inhibitors (SSRIs) and breast cancer risk.

FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.

"The government really didn't rise to the challenge the way that it should have,” notes Ben Jones, vice president of government relations and public policy for The US Oncology Network. “Practices were in distress…stretching all resources to figure out workarounds."

Idecabtagene vicleucel (ide-cel) was able to triple progression-free survival and reduce the risk of disease progression or death in a phase 3 trial.

Kathy Oubre, MS, CEO of Pontchartrain Cancer Center, is 1 of 6 cochairs for the 2024 Community Oncology Conference, and here she discusses how meeting content has incorporated ongoing coverage of the extremely disruptive cyberattack and how there is still so much work to be done.

Patients with hidradenitis suppurativa (HS) in Canada often wait long periods of time to receive an HS diagnosis and receive evidence-based therapy, highlighting the need for increased interdisciplinary education on HS management.

A new study found that tumor sites in stage I-III colorectal cancer (CRC) could affect recurrence-free survival and survival after recurrence in patients.

Researchers developed a web server that can help predict therapeutic responses to combination lenvatinib and immune checkpoint inhibitors in patients with unresectable hepatocellular carcinoma (HCC).

Patients with systemic lupus erythematosus (SLE) and atrial fibrillation (AF) exhibited elevated risks of severe cardiac complications, alongside increased in-hospital mortality, costs, and length of stay (LOS).

A retrospective study analyzing tissue assays from patients with cutaneous melanoma demonstrated the promise of yes-associated protein (YAP) as a predictive biomarker for melanoma prognosis.

CMS finalizes policies to enhance consumer protections, promote competition, and expand access to care for Medicare Advantage (MA) and Medicare Part D; digital therapeutic Rejoyn receives FDA clearance for adults with major depressive disorder (MDD); study reveals minimal symptom reduction from nirmatrelvir–ritonavir (Paxlovid) in high-risk, fully vaccinated patients.

Jonathan E. Levitt, Esq, founding partner of boutique health care law firm Frier Levitt, LLC, discusses a recent class-action lawsuit brought against Johnson & Johnson in which an employee alleged a breach of fiduciary duty regarding her employer-sponsored pharmacy benefits.

Findings from this new study demonstrate the safety and efficacy of rIX-FP among a group of treatment-naive patients often characterized by young age and particular risk for severe bleeding.